CFI-402257 |
| カタログ番号GC18491 |
CFI-402257はMps1の選択的阻害剤であり、CFI-402257はIC50値が1でMps1を阻害する。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1610759-22-2
Sample solution is provided at 25 µL, 10mM.
CFI-402257 is a selective inhibitor of Mps1, CFI-402257 inhibited Mps1 with an IC50 value of 1.2 ± 0.4 nM, and was ATP competitive with a Ki value of 0.09 ± 0.02 nM, It has high specificity, selectivity and potency [2,7].
CFI-402257 induces senescence-like responses and SASP secretion in HCC[1]. CFI-402257 suppresses MM(Malignant mesothelioma) growth. Mps-1 is overexpressed in MM and that its expression correlates with poor patients' outcome. In vitro, CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe[3]. CFI-402257, significantly inhibited GBM cell proliferation and improved the growth-suppressive effect of TMZ[4]. When evaluated the cellular effects of the potent clinical TTKi CFI-402257 in TNBC models. CFI-402257 induced apoptosis and potentiated aneuploidy in TNBC lines by accelerating progression through mitosis and inducing mitotic segregation errors[6].
In BALB/cAnN - nu mice, TTK inhibition by CFI-402257 shrank HCC tumors and reduced lung metastasis[1]. Oral QD of CMI-402257 showed dose-dependent activity in mice with established tumors in xenografts of MDA-MB-231 human TNBC cells[2]. Developed a panel of CDK4/6i-resistant breast cancer cell lines and patient-derived organoids, TTK inhibitor CFI-402257 as a therapeutic strategy for a defined subset of ER+ breast cancer patients who develop resistance to CDK4/6i[6].
References:
[1]: Chan CY, Chiu DK, et,al. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2119514119. doi: 10.1073/pnas.2119514119. Epub 2022 Aug 1. PMID: 35914158; PMCID: PMC9371652.
[2]: Mason JM, Wei X, et,al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. doi: 10.1073/pnas.1700234114. Epub 2017 Mar 7. PMID: 28270606; PMCID: PMC5373378.
[3]: Szymiczek A, Carbone M, et,al. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31. PMID: 28759042; PMCID: PMC5690838.
[4]: Yu J, Gao G, et,al.TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. BMC Cancer. 2022 Jul 18;22(1):786. doi: 10.1186/s12885-022-09899-1. PMID: 35850753; PMCID: PMC9290216.
[5]: Thu KL, Silvester J, et,al.Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577. doi: 10.1073/pnas.1719577115. Epub 2018 Jan 29. PMID: 29378962; PMCID: PMC5816201.
[6]: Soria-Bretones I, Thu KL, et,al.The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations. Sci Adv. 2022 Sep 9;8(36):eabq4293. doi: 10.1126/sciadv.abq4293. Epub 2022 Sep 7. PMID: 36070391; PMCID: PMC9451148.
[7]: Laufer R, Li SW, et,al. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3562-6. doi: 10.1016/j.bmcl.2016.06.021. Epub 2016 Jun 9. PMID: 27335255.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *